Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Pharvaris N.V.
  6. Summary
    PHVS   NL00150005Y4

PHARVARIS N.V.

(PHVS)
  Report
Delayed Nasdaq  -  10:12 2022-12-05 am EST
2.000 USD   +1.01%
11/10Pharvaris to Present PHVS416 and PHVS719 Clinical Data for Treatment of HAE at the ACAAI Annual Scientific Meeting 2022
GL
10/07Pharvaris Presents Data Supporting HAE Drug Development Strategy at the 2022 HAEi Global Leadership Workshop
GL
10/07Pharvaris Presents Data Supporting HAE Drug Development Strategy at the 2022 HAEi Global Leadership Workshop
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/29/2022 11/30/2022 12/01/2022 12/02/2022 12/05/2022 Date
2.11(c) 2.11(c) 2.09(c) 1.98(c) 2 Last
9 550 30 039 16 683 38 081 1 462 Volume
-5.17% 0.00% -0.95% -5.26% +1.01% Change
More quotes
Estimated financial data (e)
Sales 2022 - - -
Net income 2022 -69,8 M -73,2 M -73,2 M
Net cash position 2022 157 M 165 M 165 M
P/E ratio 2022 -0,96x
Yield 2022 -
Sales 2023 - - -
Net income 2023 -97,6 M -102 M -102 M
Net cash position 2023 113 M 118 M 118 M
P/E ratio 2023 -0,85x
Yield 2023 -
Capitalization 63,8 M 66,9 M 66,9 M
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 47
Free-Float 90,4%
More Financials
Company
Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE). 
More about the company
Ratings of Pharvaris N.V.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about PHARVARIS N.V.
11/10Pharvaris to Present PHVS416 and PHVS719 Clinical Data for Treatment of HAE at the ACAA..
GL
10/07Pharvaris Presents Data Supporting HAE Drug Development Strategy at the 2022 HAEi Globa..
GL
10/07Pharvaris Presents Data Supporting HAE Drug Development Strategy at the 2022 HAEi Globa..
AQ
10/07Pharvaris Presents Data Supporting HAE Drug Development Strategy At the 2022 HAEi Globa..
CI
09/30Pharvaris Announces the Promotion of Annick Deschoolmeester to Chief Human Resources Of..
GL
09/30Pharvaris Announces the Promotion of Annick Deschoolmeester to Chief Human Resources Of..
AQ
09/30Pharvaris Announces the Promotion of Annick Deschoolmeester to Chief Human Resources Of..
CI
09/19Pharvaris N.V.(NasdaqGS:PHVS) dropped from S&P Global BMI Index
CI
09/16Pharvaris Reports Data Supporting Development of PHA121 to Treat, Prevent HAE Attacks
MT
09/16Pharvaris Highlights Data Supporting Clinical Development Program for Hereditary Angioe..
GL
09/16Pharvaris Highlights Data Supporting Clinical Development Program for Hereditary Angioe..
AQ
09/14SVB Securities Adjusts Price Target on Pharvaris to $20 From $25, Keeps Outperform Rati..
MT
09/12Pharvaris Q2 Loss Narrows
MT
09/12Pharvaris Reports Second Quarter 2022 Financial Results and Provides Business Update
GL
09/12Pharvaris Reports Second Quarter 2022 Financial Results and Provides Business Update
GL
More news
News in other languages on PHARVARIS N.V.
10/07Pharvaris présente des données soutenant la stratégie de développement de médicaments c..
09/30Pharvaris annonce la promotion d'Annick Deschoolmeester au poste de directrice des ress..
09/16Pharvaris rapporte des données soutenant le développement du PHA121 pour traiter et pré..
09/12Pharvaris réduit sa perte au deuxième trimestre
09/12Pharvaris N.V. annonce ses résultats pour le deuxième trimestre et le semestre clos le ..
More news
Analyst Recommendations on PHARVARIS N.V.
More recommendations
Chart PHARVARIS N.V.
Duration : Period :
Pharvaris N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PHARVARIS N.V.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 1,89 €
Average target price 15,27 €
Spread / Average Target 709%
EPS Revisions
Managers and Directors
Berndt A. E. Modig Chief Executive Officer & Executive Director
Anna Nijdam Principal Accounting Officer & Head-Finance
David P. Meeker Chairman
Jochen Knolle Chief Operating & Scientific Officer
Peng Lu Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PHARVARIS N.V.-86.24%67
MODERNA, INC.-28.20%70 055
IQVIA HOLDINGS INC.-22.83%40 441
LONZA GROUP AG-33.82%39 802
ALNYLAM PHARMACEUTICALS, INC.38.22%28 838
SEAGEN INC.-20.82%22 727